Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.46 |
| ▸ | BTK | Q06187 | 11/20 | 0.46 |
| ▸ | ATR | Q13535 | 7/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24429388 | 0.84 | RET (0.42) | PIK3CDRET | |
| SCHEMBL16655487 | 0.79 | PIK3CD (0.52) | PIK3CDBTKATR | |
| SCHEMBL14635974 | 0.74 | RPS6KA5 (0.39) | PIK3CDBTKRET | |
| SCHEMBL14635975 | 0.74 | RPS6KA5 (0.39) | PIK3CDBTKRET | |
| Hydrochloric Acid SCHEMBL21903713 | 0.74 | RPS6KA5 (0.38) | PIK3CDBTKRET | |
| Hydrochloric Acid SCHEMBL21903715 | 0.74 | RPS6KA5 (0.38) | PIK3CDBTKRET | |
| SCHEMBL5814555 | 0.74 | RET (0.38) | PIK3CDBTKRET | |
| Hydrochloric Acid SCHEMBL31684272 | 0.74 | RPS6KA5 (0.38) | PIK3CDBTKRET | |
| SCHEMBL16655602 | 0.74 | PIK3CD (0.73) | PIK3CDBTKATR | |
| SCHEMBL16655203 | 0.74 | PIK3CD (0.73) | PIK3CDBTKATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-3057951-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | Janssen Pharmaceutica N.V. (BE) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015057205-A1 | METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | PIK3CD 2/4885BTK 1/4885ATR 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.